Spring's onset brings pollen, allergies and - for many - asthma, which for as much as 35 percent of patients falls into the category of "uncontrolled." That's the high end of the estimated subset of about 22 million adult asthmatics in the U.S., and about the same number overseas. Corticosteroids aren't getting the job done, but which new target can, in a crowded market worth about $12.7 billion worldwide, according to GlobalData? Read More
